<p>(<b>A</b>) superpositions of MIP-MDM2 fusion (PDB ID = 2RUH), DI:MDM2 (3G03), PMI:MDM2 (3EQS), and p53 peptide:MDM2 (1YCR) in ribbons, viewed as in Fig. 2A, right. Each component is color coded: MIP (brown)-MDM2 (orange), DI (blue):MDM2 (cyan), PMI (pink):MDM2 (purple), and the p53 peptide (green):MDM2 (light green). (<b>B</b>) MIP, DI, PMI, and p53 peptide are presented as two opposite views. W4, Y6, and M11 of MIP cover the hydrophobic patches on the surface of MDM2, as shown in Fig. 2C, left. These residues and the Phe-Trp-Leu triad, and the corresponding residues in DI, PMI, and the p53 peptide are displayed as sticks. (<b>C</b>) A-zoomed-in view of the hydrophobic contacts formed around W4 and M11 of MIP. Fig. 3A, Fig. 3B (left), an...
p53 is a tumor suppressor protein that prevents tumorigenesis through cell cycle arrest or apoptosis...
Peptide inhibition of the interactions of the tumor suppressor protein P53 with its negative regulat...
The complex between the proteins MDM2 and p53 is a promising drug target for cancer therapy. The res...
The oncoprotein MDM2 binds to tumor suppressor protein p53 and inhibits its anticancer activity, whi...
<p>(<b>A, left</b>) Superpositioning of backbone heavy atoms of the 20 MIP-MDM2 three-dimensional st...
<div><p>(A) MDM2 peptide (red) binds to the same surface groove as the p53 peptide (magenta). Residu...
MDM2 is a negative regulator of p53. The N terminal domain of MDM2 interacts with a helical region o...
<p>(<b>A</b>) A network of hydrogen bonding and hydrophobic interactions formed by the phosphorylate...
<div><p>(A) Overall structure of the HAUSP TRAF-like domain bound to MDM2 peptide is shown in a ribb...
<p>(A) The structure of the N-terminus (p53-binding domain) of MDM2 (1YCR) showing the positions of ...
MDM2 is a negative regulator of p53. The N terminal domain of MDM2 interacts with a helical region o...
15 pags., 6 figs., 3 tabs. -- Open Access funded by Creative Commons Atribution Licence 4.0p53 is f...
<p>(<b>A</b>) Schematic diagram of the HAT-GB1 fused MIP-MDM2-T7tag protein expression plasmid. The ...
The conformational landscapes of p53 peptide variants and phage derived peptide (12/1) variants, all...
<p>Only the tryptophan residue of each peptide (with 6-chloro group shown in green for M011) and ami...
p53 is a tumor suppressor protein that prevents tumorigenesis through cell cycle arrest or apoptosis...
Peptide inhibition of the interactions of the tumor suppressor protein P53 with its negative regulat...
The complex between the proteins MDM2 and p53 is a promising drug target for cancer therapy. The res...
The oncoprotein MDM2 binds to tumor suppressor protein p53 and inhibits its anticancer activity, whi...
<p>(<b>A, left</b>) Superpositioning of backbone heavy atoms of the 20 MIP-MDM2 three-dimensional st...
<div><p>(A) MDM2 peptide (red) binds to the same surface groove as the p53 peptide (magenta). Residu...
MDM2 is a negative regulator of p53. The N terminal domain of MDM2 interacts with a helical region o...
<p>(<b>A</b>) A network of hydrogen bonding and hydrophobic interactions formed by the phosphorylate...
<div><p>(A) Overall structure of the HAUSP TRAF-like domain bound to MDM2 peptide is shown in a ribb...
<p>(A) The structure of the N-terminus (p53-binding domain) of MDM2 (1YCR) showing the positions of ...
MDM2 is a negative regulator of p53. The N terminal domain of MDM2 interacts with a helical region o...
15 pags., 6 figs., 3 tabs. -- Open Access funded by Creative Commons Atribution Licence 4.0p53 is f...
<p>(<b>A</b>) Schematic diagram of the HAT-GB1 fused MIP-MDM2-T7tag protein expression plasmid. The ...
The conformational landscapes of p53 peptide variants and phage derived peptide (12/1) variants, all...
<p>Only the tryptophan residue of each peptide (with 6-chloro group shown in green for M011) and ami...
p53 is a tumor suppressor protein that prevents tumorigenesis through cell cycle arrest or apoptosis...
Peptide inhibition of the interactions of the tumor suppressor protein P53 with its negative regulat...
The complex between the proteins MDM2 and p53 is a promising drug target for cancer therapy. The res...